Drug
Benmelstobart clinical trials
Also written TQB2450.
- studies test it
- 67
- open now
- 34
- in phase 3
- 15
- first study started
- 2018
Keep track of what changes. Save the benmelstobart studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
- TQB2450
- 26
Combined with it in one product
Studies by the year they started
67 studies that test it; most in 2020 (10)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2019 | 8 |
| 2020 | 10 |
| 2021 | 7 |
| 2022 | 6 |
| 2023 | 9 |
| 2024 | 10 |
| 2025 | 7 |
| 2026 | 9 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 11
- Phase 2
- 46
- Phase 3
- 15
- Phase 4
- 1
- No phase
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 29 · Other 38
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (28) · Sun Yat-sen University (4) · Henan Cancer Hospital (3) · Tianjin Medical University Cancer Institute and Hospital (3) · Fudan University (3) · Shanghai Pulmonary Hospital, Shanghai, China (3) · The First Affiliated Hospital of Zhengzhou University (2) · RenJi Hospital (2)
Often tested with
Tested in the same studies.
Anlotinib (34) · Catequentinib hydrochloride (12) · Paclitaxel (7) · Albumin-Bound Paclitaxel (5) · Carboplatin (4) · Cisplatin (3) · Oxaliplatin (2) · Etoposide (2)
Studies
Open first, then newest update. How each study uses benmelstobart is read from its arms, and is right about nine times in ten.
Testing it · 67
- Efficacy and Safety of Induction Benmelstobart Plus Anlotinib and Chemotherapy Followed by Concurrent Chemoradiotherapy and Benmelstobart Maintenance Versus Concurrent Chemoradiotherapy Followed by Benmelstobart Maintenance in Patients With Unresectable Stage III NSCLCNot yet recruitingPhase 2The Third Xiangya Hospital of Central South UniversityNCT07643350Written as Benmelstobart
- Anlotinib + Benmelstobart vs Surgery for Patients With Localized Renal Cell Carcinoma Scheduled to Undergo Partial NephrectomyNot yet recruitingPhase 2Tianjin Medical University Cancer Institute and HospitalNCT07627464Written as Anlotinib hydrochloride + Benmelstobart + Partial nephrectomy
- TQB2450 Plus Progestin for Fertility-sparing Treatment in MMRd ECRecruitingPhase 2Fudan UniversityNCT06914297Written as TQB2450 injection + oral progestin
- Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant TherapyRecruitingPhase 2Fudan UniversityNCT05582499Written as Benmelstobart
- Neoadjuvant PD-L1 Inhibitor Plus Anlotinib for Kidney Preservation in Complex Renal Cell CarcinomaNot yet recruitingPhase 2RenJi HospitalNCT07602101Written as TQB2450 + Anlotinib
- Postoperative Radiotherapy With Nimotuzumab ± Benmelstobart in Intermediate-Risk Head and Neck Squamous Cell CarcinomaNot yet recruitingPhase 2/3Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityNCT07535567Written as Nimotuzumab, Benmelstobart
- A Study of Benmelstobart, Anlotinib, Chemotherapy and Thoracic Radiotherapy for People With Extensive-stage Small Cell Lung CancerNot yet recruitingPhase 2Yayi HeNCT07538271Written as benmelstobart
- Benmelstobart Plus Anlotinib, Chemotherapy and Thoracic Radiation for Limited-Stage Small Cell Lung CancerNot yet recruitingPhase 2Yayi HeNCT07538258Written as Benmelstobart
- Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted TherapyNot yet recruitingPhase 2Nanfang Hospital, Southern Medical UniversityNCT07537777Written as Benmelstobart
- A Phase II Study of Benmelstobart + Anlotinib + Chemotherapy as First-Line Treatment for LCNEC and EP-NECNot yet recruitingPhase 2Tianjin Medical University Cancer Institute and HospitalNCT07510594Written as Benmelstobart+ Anlotinib+ Platinum + Etoposide
- Anlotinib and Benmelstobart in DTCNot yet recruitingPhase 2Fudan UniversityNCT07193186Written as Anlotinib and Benmelstobart
- Garsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NSCLCNot yet recruitingPhase 2Sun Yat-sen UniversityNCT07294261Written as Garsorasib, Benmelstobart, Anlotinib
- A Clinical Trial Evaluating TQB2102 for Injection in Combination With Behmosubaisumab/Payamprolizumab With or Without Chemotherapy in Unresectable Locally Advanced, Recurrent, or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastroesophageal AdenocarcinomaRecruitingPhase 2Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.NCT06767800Written as TQB2102 for injection (7.5 mg) +Benmelstobart+Chemotherapy
- Umbrella Trial of Adjuvant Therapy in Completely Resected High-risk Stage IA-IB NSCLC: Focus on Driver MutationsNot yet recruitingPhase 3The First Affiliated Hospital of Guangzhou Medical UniversityNCT06955325Written as Benmelstobart
- Anlotinib Combined With Benmelstobart for Advanced PheochromocytomaNot yet recruitingPhase 2Sun Yat-sen UniversityNCT06429397Written as Anlotinib and Benmelstobart
- Benmelstobart, Anlotinib and Chemotherapy as First-line Treatment for Extensive-stage Small-cell Lung CancerNot yet recruitingPhase 4Peking Union Medical College HospitalNCT06931145Written as Benmelstobart
- Benmelstobart Combined With Radiochemotherapy as Neoadjuvant Treatment Iin ESCCRecruitingPhase 2Shanghai Zhongshan HospitalNCT06637163Written as Benmelstobart+ Paclitaxel + Carboplatin+ Radiotherapy
- Phase II Study of Golidocitinib and Benmelstobart in Patients with R/R ENKTL (JACKPOT50)RecruitingPhase 2Sun Yat-sen UniversityNCT06733051Written as Benmelstobart
- Neoadjuvant Therapy of Targeted Immunotherapy Combined With Chemotherapy for Locally Advanced HNSCCNot yet recruitingPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT06699498Written as Benmelstobart
- Anlotinib Plus Benmelstobart and AG in First-line Treatment of Advanced Metastatic Pancreatic Cancer (ALTER-PA-001)Not yet recruitingPhase 2RenJi HospitalNCT06621095Written as anlotinib + benmelstobart + nab-paclitaxel + gemcitabine
See all 67 studies that test benmelstobart →
Given in every arm · 6 — benmelstobart is usual care beside what is tested
- A LM-302 Combination With Other Anti-Tumor Therapies Phase ll StudyRecruitingPhase 2LaNova Medicines Zhejiang Co., Ltd.NCT05934331Written as Benmelstobart
- Anlotinib Plus Immunotherapy and Chemoradiotherapy for High-Risk Nasopharyngeal CarcinomaNot yet recruitingPhase 3Sun Yat-sen UniversityNCT07385079Written as Benmelstobart
- An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid TumorsRecruitingPhase 1/2Beijing Tide Pharmaceutical Co., LtdNCT07371663Written as benmelstobart Injection
- Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung CancerNot yet recruitingPhase 2Tianjin Medical University Cancer Institute and HospitalNCT07172412Written as Tislelizumab/Atezolizumab/ Durvalumab/Benmelstobart/Toripalimab/Serplulimab
- Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.TerminatedPhase 2Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT05481645Written as TQB2450 injection
- A Clinical Trial of TQB2450 Injection Combined With AL2846 Capsules in Patients With Advanced Solid TumorsActive, not recruitingPhase 1Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT06116240Written as TQB2450 injection
As the comparator · 1 — what is tested is compared with benmelstobart
Codes
What other systems call benmelstobart · ClinicalTrials.gg INT016056
- UNII (FDA) B25CF42QKPBENMELSTOBARTOne source FDA
- NCI Thesaurus C156692BenmelstobartOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | B25CF42QKP | BENMELSTOBART | One source FDA |
| NCI Thesaurus | C156692 | Benmelstobart | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.